{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:56:23Z","timestamp":1781157383617,"version":"3.54.1"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejca.2026.116820","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T16:14:37Z","timestamp":1779725677000},"page":"116820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The survival impact of combining radiotherapy and immune checkpoint inhibitors in patients with solid tumors: A systematic review and living meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"242","author":[{"given":"Mathijs L.","family":"Tomassen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7669-8156","authenticated-orcid":false,"given":"Claudia E.","family":"Pronk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost J.C.","family":"Verhoeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9902-4592","authenticated-orcid":false,"given":"Ben J.","family":"Slotman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1274-5643","authenticated-orcid":false,"given":"Hanneke W.M.","family":"van Laarhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1111-608X","authenticated-orcid":false,"given":"Idris","family":"Bahce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abrahim","family":"Al-Mamgani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja D.","family":"de Gruijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3995-2204","authenticated-orcid":false,"given":"Suresh","family":"Senan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5204-1774","authenticated-orcid":false,"given":"Famke L.","family":"Schneiders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4243-8388","authenticated-orcid":false,"given":"Peter S.N.","family":"van Rossum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2026.116820_bib1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jjco\/hyaa268","article-title":"The role of radiotherapy in the age of immunotherapy","volume":"51","author":"Sato","year":"2021","journal-title":"Jpn J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2026.116820_bib2","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1016\/S1470-2045(24)00075-5","article-title":"Radiotherapy, immunity, and immune checkpoint inhibitors","volume":"25","author":"Lynch","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1076","key":"10.1016\/j.ejca.2026.116820_bib3","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170157","article-title":"Combining radiotherapy with immunotherapy: the past, the present and the future","volume":"90","author":"Van Limbergen","year":"2017","journal-title":"Br J Radio"},{"issue":"4","key":"10.1016\/j.ejca.2026.116820_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.70030","article-title":"Leveraging radiotherapy to improve immunotherapy outcomes: rationale, progress and research priorities","volume":"14","author":"Hartley","year":"2025","journal-title":"Clin Transl Immunol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116820_bib5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1158\/1535-7163.MCT-18-0558","article-title":"TGF\u03b2 Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies","volume":"18","author":"Rodr\u00edguez-Ruiz","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.ejca.2026.116820_bib6","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1962592","article-title":"LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells","volume":"10","author":"Yamazaki","year":"2021","journal-title":"Oncoimmunology"},{"issue":"8","key":"10.1016\/j.ejca.2026.116820_bib7","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1158\/2326-6066.CIR-19-0338","article-title":"Radiotherapy Cooperates with IL15 to Induce Antitumor Immune Responses","volume":"8","author":"Pilones","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"2 Pt 1","key":"10.1016\/j.ejca.2026.116820_bib8","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","article-title":"Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer","volume":"11","author":"Demaria","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ejca.2026.116820_bib9","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.ymthe.2018.09.008","article-title":"Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape","volume":"26","author":"DeSelm","year":"2018","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.ejca.2026.116820_bib10","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2158013","article-title":"Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors","volume":"12","author":"Laurent","year":"2023","journal-title":"Oncoimmunology"},{"issue":"24","key":"10.1016\/j.ejca.2026.116820_bib11","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"issue":"16_","key":"10.1016\/j.ejca.2026.116820_bib12","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1200\/JCO.2025.43.16_suppl.4000","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC\/GEJC) following neoadjuvant chemoradiotherapy (CRT): first results of overall survival (OS) from CheckMate 577","volume":"43","author":"Kelly","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2026.116820_bib13","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116820_bib14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1109","key":"10.1016\/j.ejca.2026.116820_bib15","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20200042","article-title":"The abscopal effect 67 years later: from a side story to center stage","volume":"93","author":"Demaria","year":"2020","journal-title":"Br J Radio"},{"issue":"1","key":"10.1016\/j.ejca.2026.116820_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188386","article-title":"Priming the tumor immune microenvironment with chemo(radio)therapy: a systematic review across tumor types","volume":"1874","author":"van den Ende","year":"2020","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2026.116820_bib17","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.21037\/tlcr-20-304","article-title":"An overview of the published and running randomized phase 3 clinical results of radiotherapy in combination with immunotherapy","volume":"10","author":"Vanneste","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2026.116820_bib18","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.trecan.2016.05.002","article-title":"Radiotherapy: changing the Game in Immunotherapy","volume":"2","author":"Demaria","year":"2016","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2026.116820_bib19","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.ejca.2026.116820_bib20","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1016\/S1470-2045(24)00656-9","article-title":"Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation","volume":"26","author":"Morris","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116820_bib21","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.ejca.2026.116820_bib22","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2165\/11594010-000000000-00000","article-title":"Ipilimumab","volume":"71","author":"Cameron","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.ejca.2026.116820_bib23","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2026.116820_bib24","unstructured":"Higgins J.P.T.T.J., Chandler J., Cumpston M., Li T., Page M.J., Welch V.A. (editors). Cochrane Handbook for Systematic Reviews of Interventions. Cochrane2024. Available from: Available from www.training.cochrane.org\/handbook."},{"key":"10.1016\/j.ejca.2026.116820_bib25","unstructured":"Higgins K.A., Hu C., Ross H.J., Jabbour S.K., Kozono D.E., Owonikoko T.K., et al. Chemoradiation \u00b1 Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology\/Alliance LU005. Journal of Clinical Oncology.0(0):JCO\u201325\u201301569."},{"issue":"2","key":"10.1016\/j.ejca.2026.116820_bib26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1470-2045(21)00630-6","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2026.116820_bib27","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116820_bib28","article-title":"Stereotactic Body Radiotherapy (SBRT) With Pembrolizumab (pembro) for Unresected Stage I\/II Non-Small-Cell Lung Cancer (NSCLC): The Randomized, Double-Blind, Phase 3 KEYNOTE-867 Study","author":"Pircher SS","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116820_bib29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-025-01768-1","article-title":"PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy","volume":"18","author":"Wu","year":"2025","journal-title":"J Hematol & Oncol"},{"issue":"16_","key":"10.1016\/j.ejca.2026.116820_bib30","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1200\/JCO.2025.43.16_suppl.8012","article-title":"The preliminary results of a randomized phase II trial evaluating induction toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab in bulky unresectable stage III non-small-cell lung cancer (InTRist)","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116820_bib31","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1470-2045(21)00658-6","article-title":"Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial","volume":"23","author":"Schoenfeld","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116820_bib32","article-title":"A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiation Therapy in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD)","author":"Kothari","year":"2025","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"issue":"5","key":"10.1016\/j.ejca.2026.116820_bib33","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"10405","key":"10.1016\/j.ejca.2026.116820_bib34","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(23)01384-3","article-title":"Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial","volume":"402","author":"Chang","year":"2023","journal-title":"Lancet"},{"issue":"_3","key":"10.1016\/j.ejca.2026.116820_bib35","first-page":"1","article-title":"Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2","volume":"9","author":"Bradley SS","year":"2024","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2026.116820_bib36","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N Engl J Med"},{"issue":"16_","key":"10.1016\/j.ejca.2026.116820_bib37","doi-asserted-by":"crossref","first-page":"8098","DOI":"10.1200\/JCO.2024.42.16_suppl.8098","article-title":"A randomized phase II study of toripalimab consolidation or observation after concurrent chemoradiotherapy in limited-stage small cell lung cancer","volume":"42","author":"Zhang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116820_bib38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.annonc.2021.09.011","article-title":"Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP\/IFCT 4-12 STIMULI trial","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2026.116820_bib39","article-title":"AdvanTIG-204: A Phase 2, Randomized, Open-Label Study of Ociperlimab Plus Tislelizumab and Concurrent Chemoradiotherapy Versus Tislelizumab and Concurrent Chemotherapy Versus Concurrent Chemoradiotherapy in First-Line Limited-Stage SCLC","volume":"6","author":"Gong","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.ejca.2026.116820_bib40","doi-asserted-by":"crossref","unstructured":"Owonikoko T.K., Higgins K.A., Chen Z., Zhang C., Pillai R.N., Steuer C.E., et al. A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC). Journal of Clinical Oncology.37(15_suppl):8515\u2013.","DOI":"10.1200\/JCO.2019.37.15_suppl.8515"},{"issue":"1","key":"10.1016\/j.ejca.2026.116820_bib41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116820_bib42","article-title":"Ipilimumab with temozolomide vs. temozolomide alone after surgery and chemoradiotherapy in recently diagnosed glioblastoma: a randomized phase II clinical trial","volume":"7","author":"Brown","year":"2025","journal-title":"Neuro-Oncol Adv"},{"issue":"1","key":"10.1016\/j.ejca.2026.116820_bib43","article-title":"NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma","volume":"5","author":"Sim","year":"2023","journal-title":"Neurooncol Adv"},{"issue":"ement_5","key":"10.1016\/j.ejca.2026.116820_bib44","article-title":"RADT-31. Hypo-fractionated stereotactic re-irradiation (HFSRT) Plus durvalumab vs hfsrt re-irradiation alone for patients with a recurrent glioblastoma: results of the comparative randomized phase ii sterimgli trial","volume":"27","author":"Cabarrou","year":"2025","journal-title":"Neuro-Oncol"},{"issue":"16_","key":"10.1016\/j.ejca.2026.116820_bib45","doi-asserted-by":"crossref","first-page":"6013","DOI":"10.1200\/JCO.2025.43.16_suppl.6013","article-title":"Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC)","volume":"43","author":"Tao","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116820_bib46","unstructured":"Bourhis J., Aup\u00e9rin A., Borel C., Lefebvre G., Racadot S., Geoffrois L., et al. Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial. The Lancet."},{"issue":"1","key":"10.1016\/j.ejca.2026.116820_bib47","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer","volume":"393","author":"Uppaluri","year":"2025","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ejca.2026.116820_bib48","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1001\/jama.2025.1483","article-title":"Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial","volume":"333","author":"Haddad","year":"2025","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.ejca.2026.116820_bib49","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jama.2025.1132","article-title":"Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial","volume":"333","author":"Liang","year":"2025","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.ejca.2026.116820_bib50","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(24)00504-7","article-title":"Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial","volume":"25","author":"Liu","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10445","key":"10.1016\/j.ejca.2026.116820_bib51","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","article-title":"Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"403","author":"Liu","year":"2024","journal-title":"Lancet"},{"issue":"10434","key":"10.1016\/j.ejca.2026.116820_bib52","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ejca.2026.116820_bib53","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S1470-2045(23)00479-5","article-title":"Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial","volume":"24","author":"Monk","year":"2023","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116820_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2024.100070","article-title":"Academic Randomized Phase II Trial Assessing The Inhibitor Of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab In Combination With Chemoradiation In Locally Advanced Cervical Cancer (ATEZOLACC Trial)","volume":"35","author":"Chargari","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2026.116820_bib55","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1002\/cncr.34176","article-title":"Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma","volume":"128","author":"Park","year":"2022","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2026.116820_bib56","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1056\/NEJMoa2502449","article-title":"Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma","volume":"393","author":"Rischin","year":"2025","journal-title":"N Engl J Med"},{"issue":"16_","key":"10.1016\/j.ejca.2026.116820_bib57","doi-asserted-by":"crossref","first-page":"6000","DOI":"10.1200\/JCO.2025.43.16_suppl.6000","article-title":"Phase 3 randomized trial (KEYNOTE-630) of adjuvant pembrolizumab (pembro) versus placebo (pbo) for high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) following surgery and radiation (RT)","volume":"43","author":"Koyfman","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10467","key":"10.1016\/j.ejca.2026.116820_bib58","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(24)01812-9","article-title":"Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial","volume":"404","author":"Mowery","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2026.116820_bib59","article-title":"Clinical Efficacy of PD-1 Inhibitors Plus Split-Course Radiotherapy in the First-Line Treatment of Advanced Kidney Cancer: A Randomized Controlled Trial","volume":"2022","author":"Li","year":"2022","journal-title":"J Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116820_bib60","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(22)00066-3","article-title":"Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial","volume":"23","author":"Zhu","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116820_bib61","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.eururo.2020.07.032","article-title":"Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors","volume":"78","author":"Fizazi","year":"2020","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.ejca.2026.116820_bib62","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jamaoncol.2023.2132","article-title":"Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial","volume":"9","author":"Spaas","year":"2023","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2026.116820_bib63","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/1878-0261.12658","article-title":"Radiotherapy\u2013immunotherapy combinations \u2013 perspectives and challenges","volume":"14","author":"Mondini","year":"2020","journal-title":"Mol Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2026.116820_bib64","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/S1470-2045(19)30171-8","article-title":"Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy","volume":"20","author":"Deutsch","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116820_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100867","article-title":"Synergizing radiotherapy and immunotherapy: Current challenges and strategies for optimization","volume":"36","author":"Rajeev-Kumar","year":"2023","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.ejca.2026.116820_bib66","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1038\/s41467-022-34676-w","article-title":"Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors","volume":"13","author":"Darragh","year":"2022","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.ejca.2026.116820_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013237","article-title":"Immune-modulating effects on tumor-draining lymph nodes of neoadjuvant chemoradiotherapy combined with dual immunotherapy in patients with T3-4N0-2 NSCLC","volume":"13","author":"Ulas","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116820_bib68","unstructured":"van Rossum P.S.N., Damen P.J.J., Cortiula F., Hobbs B.P., De Marchi L., Mohan R., et al. Pretreatment risk model for radiation-induced lymphopenia is associated with adjuvant durvalumab efficacy in patients with unresectable stage III NSCLC. International Journal of Radiation Oncology, Biology, Physics."},{"key":"10.1016\/j.ejca.2026.116820_bib69","series-title":"International Review of Cell and Molecular Biology. 378","first-page":"1","article-title":"Chapter One - Radio-induced lymphopenia in the era of anti-cancer immunotherapy","author":"de Kermenguy","year":"2023"},{"issue":"8","key":"10.1016\/j.ejca.2026.116820_bib70","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/S1470-2045(19)30157-3","article-title":"Integration of radiotherapy and immunotherapy for treatment of oligometastases","volume":"20","author":"Pitroda","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2026.116820_bib71","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","article-title":"The adenosine pathway in immuno-oncology","volume":"17","author":"Allard","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116820_bib72","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-021-01053-x","article-title":"Novel therapies emerging in oncology to target the TGF-\u03b2 pathway","volume":"14","author":"Kim","year":"2021","journal-title":"J Hematol & Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2026.116820_bib73","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.jtho.2024.06.024","article-title":"Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC","volume":"19","author":"Jun","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116820_bib74","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008125","article-title":"Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma","volume":"12","author":"Versluis","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2026.116820_bib75","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012743","article-title":"Positive and negative roles of myeloid cells in cancer immunotherapy","volume":"13","author":"Zak","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116820_bib76","article-title":"Harnessing TCR repertoires: predictive insights and therapeutic monitoring in cancer immunotherapy","volume":"28","author":"Chiffelle","year":"2025","journal-title":"Immuno-Oncol Technol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116820_bib77","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","article-title":"The Microenvironmental Landscape of Brain Tumors","volume":"31","author":"Quail","year":"2017","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.ejca.2026.116820_bib78","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell & Mol Immunol"},{"key":"10.1016\/j.ejca.2026.116820_bib79","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ctrv.2016.11.013","article-title":"Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review","volume":"53","author":"Kroeze","year":"2017","journal-title":"Cancer Treat Rev"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:56:52Z","timestamp":1781153812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926006015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":79,"alternative-id":["S0959804926006015"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116820","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The survival impact of combining radiotherapy and immune checkpoint inhibitors in patients with solid tumors: A systematic review and living meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116820","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116820"}}